Status:
NOT_YET_RECRUITING
The Value of Novel Thrombus Markers in the Diagnosis and Treatment of Acute Pulmonary Embolism
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Acute Pulmonary Embolism
Eligibility:
All Genders
18-120 years
Brief Summary
In response to the high mortality rate of patients with acute pulmonary embolism (APE) and the fact that only a small proportion of deceased patients can receive correct diagnosis, this study will use...
Eligibility Criteria
Inclusion
- Patients diagnosed with APE for the first time through CTPA in clinical practice and who have not received anticoagulant therapy in the past month; 2.Age ≥ 18 years old.
Exclusion
- 1\. Complicated with other thrombotic diseases, complicated with important organ damage such as heart, liver, kidney, and previous history of pulmonary embolism; 2. Malignant tumors; 3. Renal dialysis patients; 4. Antiphospholipid syndrome; 5. Immune system diseases; 6. Hematological diseases; 7. DIC caused by severe infection; 8. Patients judged by clinicians to be unfit for clinical practice.
Key Trial Info
Start Date :
October 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06907238
Start Date
October 14 2025
End Date
December 31 2027
Last Update
September 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.